Moreover, persisting cytopenia and even secondary myelodysplastic syndrome (MDS) have been observed in patients with RR ALL and/or NHL treated with anti-CD19 CAR T cells (106). The gene discussed is CD19; the disease is myelodysplastic syndrome.